The involvement of alpha-2A-adrenergic receptors in attention-deficit/hyperactivity disorder (ADHD) has been early suggested by Arnsten et al., 1 who demonstrated that noradrenergic inputs from locus coeruleus to prefrontal cortex could improve cognitive function, through a2 receptors present in dopamine-containing neurons. Pharmacological evidences showing that clonidine and guanfacine, two a2-adrenergic agonists relatively selective for a2A subtype, are effective in treating ADHD symptoms 2 further suggest that this subtype of adrenergic receptor can be implicated in ADHD pathophysiology.
A putative role for alpha-2A-adrenergic receptor gene (ADRA2A) in ADHD has been initially investigated by Comings et al., 3 who detected an association of highest ADHD scores, particularly inattentive scores, with the homozygosity for the G allele. This was defined by the presence of an MspI restriction site at position -1291, created by a C > G single-nucleotide polymorphism (SNP) (rs 1800544). This association, however, has not been observed through the Transmission Disequilibrium Test (TDT) in a subsequent report. 4 In our first attempt to investigate the ADRA2A gene in a Brazilian sample of ADHD patients, the À1291 C > G SNP was analyzed in 92 subjects and their biological parents. 5 Although no association has been observed through Haplotype Relative Risk method, an influence of this variation on continuous ADHD scores was detected: the mean scores at both inattentive and combined (inattentive þ hyperactive/impulsive) symptoms were significantly higher in the probands with the GG (former mm) genotype than in probands with other genotypes.
A subsequent study from Park et al. 6 has given additional support for an involvement of ADRA2A gene in ADHD. Here, a sample of 177 nuclear families was investigated by TDT and Quantitative TDT Letters to the Editor (QTDT) for three different SNPs: the cited À1291 C > G, the rs 1800545 at 5 0 UTR and the rs 553668 at 3 0 UTR, the latter two identified respectively with HhaI and DraI restriction endonucleases. Both analyses showed positive results for the 3 0 UTR SNP. The TDT findings were not significant if the ADHD inattentive type was considered alone, but the findings were significant if the combined type was considered alone or if combined and inattentive types were considered together. Regarding QTDT analysis, positive findings were verified both with inattentive and hyperactive-impulsive symptoms. In addition, a significant effect of the À1291 C > G polymorphism has also been detected in both inattentive and hyperactive-impulsive symptom dimensions, particularly through the G allele, replicating our findings. Moreover, haplotype analyses have shown significant effects of these two polymorphisms by either TDT or QTDT. In both cases, the G allele of À1291 C > G SNP seemed to contribute to an increased risk, especially when inattentive symptoms are considered. The fact that the G allele at À1291 site is in linkage disequilibrium with the putative risk allele at 3 0 UTR polymorphic site, however, did not allow definitive conclusions on the most important marker in ADRA2A gene with respect to ADHD etiology.
To further investigate the role of ADRA2A gene (namely, the À1291 C > G SNP) in Brazilian ADHD youths, a completely new sample of probands has been collected. This sample comprised 128 new patients from the ADHD outpatient clinic at the Child and Adolescent Psychiatric Division of Hospital de Clínicas de Porto Alegre, Brazil, obtained from an ADHD pharmacogenomic study. 7 Briefly, the inclusion criteria were: (a) ADHD diagnosis according to DSM-IV criteria; 8 (b) age between 4 and 17 years old; (c) European ancestry. The symptoms at each ADHD cluster (inattention, hyperactivity/impulsivity and combined) were obtained from Swanson, Nolan, and Pelham scale -version IV (SNAP-IV), 9 a widely used standardized measure of ADHD. Primers and protocols for polymerase chain reaction amplification of genomic DNA samples and MspI digestion and electrophoresis conditions were as previously described. 5 For the objective of this study, the patients were grouped according to À1291 C > G genotypes (CC, CG and GG). Parental SNAP-IV scores were compared among the groups through ANOVA (SPSS, version 12.0). Table 1 shows that the association with inattentive symptoms was again detected, since the mean SNAP-IV scores in this dimension were significantly higher in probands with GG genotype than in probands with other genotypes (P = 0.017). No significant differences were found on hyperactive/impulsive, oppositional and total scores in the SNAP-IV. In addition, no significant differences were found among the three groups of patients according to genotypes in potential confounding variables such as gender, age, IQ, prevalence of main comorbidities and previous use of medication (data available upon request).
The results observed in the present work further suggest a role for the ADRA2A À1291 C > G polymorphism, notably the G allele, in ADHD. As pointed out by Talmud and Humphries, 10 the best way to reduce the possibility of spurious associations is to replicate the finding in a second independent study, restricted to only those traits found initially with statistical significance. Therefore, the present observation of a similar result assessed with a different methodology in an entirely different sample obtained from a population already investigated suggests that the ADRA2A gene has a role in ADHD inattentive dimension. It is important to note, however, that only 12.5% of our sample is homozygous for the putative risk allele. Moreover, the results from Park et al. 6 do not rule out the involvement of other ADRA2A gene regions in the genetic susceptibility to the disorder. Nevertheless, we believe that our findings suggest that the role of the ADRA2A gene in ADHD should be more extensively assessed in future studies. 
